This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Aug 8, 2026
•
6 min read
🧬 Human experience as a key driver in drug (re)discovery.
Aug 7, 2026
3 min read
🧬 Replimune's Tudriqev (RP1) wins FDA accelerated approval for advanced melanoma post-PD-1 therapy failure, Tarsus Pharmaceuticals acquires Alkeus Pharmaceuticals for up to $800M to develop Stargardt disease treatment, Latigo Biotherapeutics raises $345.6M IPO to advance non-opioid pain drug pipeline
Aug 6, 2026
🧬 FDA approves Moderna's mFLUVISA, first mRNA-based flu vaccine, for seasonal influenza prevention in adults 50 and older, LifeMine Therapeutics raises $263M in venture financings, advancing novel organ transplant treatment, Schrödinger expands Bristol Myers Squibb partnership with large-scale Bunsen AI co-scientist deployment
Aug 5, 2026
🧬 Eli Lilly posts record $23B Q2 revenue, driven by Mounjaro and Zepbound despite slower Foundayo launch, Icon, Anthropic partner to deploy Claude AI into clinical trials via multi-year collaboration, Gilead Sciences' HIV prevention franchise surpasses $1B quarterly sales, raises full-year HIV growth guidance
Aug 4, 2026
🧬 Otsuka's Voyxact (sibeprenlimab) stabilizes kidney function decline to normal levels in Ph3 immunoglobulin A nephropathy trial, Pathos AI, AstraZeneca, Jiangsu Alphamab Biopharmaceuticals ink dual breast cancer deals, $125M upfront, $2.093B milestones, Merck & Co. raises 2026 sales guidance to $67.3B as Keytruda, Winrevair, and Lipfendra drive growth
Aug 3, 2026
🧬 Supernus Pharmaceuticals, Indivior Pharmaceuticals merge in all-stock deal, creating $2.2B CNS company with 11 approved drugs, Novartis' Pluvicto (lutetium vipivotide tetraxetan) wins FDA approval for PSMA-positive metastatic hormone-sensitive prostate cancer label expansion, AstraZeneca, Bristol Myers Squibb reportedly in early-stage merger talks valuing combined entity at $400B
Jul 31, 2026
🧬 Replimune's (vusolimogene oderparepvec) wins positive adcomm vote for advanced melanoma in Ph1/2 combination trial, AstraZeneca, Daiichi Sankyo's Datroway (datopotamab deruxtecan) gains EU approval for first-line unresectable or metastatic triple-negative breast cancer based on Ph3 data, Regeneron posts biggest quarterly revenue growth since pandemic on booming Dupixent sales
Jul 30, 2026
🧬 Johnson & Johnson pays Sail Biomedicines $785M upfront, option to acquire for $2.58B in in vivo CAR-T deal, Eli Lilly, Resilience commit $750M to boost US diabetes and obesity medicine production, Sanofi raises 2026 outlook after Dupixent quarterly sales surpass €5B ($5.73B) milestone
Jul 29, 2026
🧬 Biogen flips 2026 revenue guidance to growth after Apellis Pharmaceuticals acquisition and strong new drug sales, AbbVie's Rinvoq (upadacitinib) earns dual EU approvals for non-segmental vitiligo and severe alopecia areata via Ph3 data, Caldera Therapeutics reverse merges with Synlogic, secures $278M financing to advance IBD bispecific antibody
Jul 28, 2026
🧬 GSK launches three-year restructuring targeting $2.5B annual cost savings by 2029 to fund pipeline growth, GSK to establish 300,000 sq ft flagship R&D centre at Cambridge Biomedical Campus, investing £400M ($531.6M), Atea Pharmaceuticals' (bemnifosbuvir/ruzasvir) matches Gilead's Epclusa in Ph3 trial for hepatitis C
Jul 27, 2026
🧬 Argenx acquires Forte Biosciences for $2.2B, gaining phase 2-stage vitiligo and celiac disease drug FB102, FDA approves Otsuka's Simtriyo (centanafadine), first norepinephrine-dopamine-serotonin reuptake inhibitor for attention-deficit hyperactivity disorder, AstraZeneca reaffirms $80B revenue target despite eplontersen trial failure and mixed pipeline results
Jul 24, 2026
🧬 Scribe Therapeutics raises nearly $129M IPO, advancing gene editing and ASCVD therapy development, Amgen submits data package to FDA seeking hearing to defend Tavneos' U.S. market status, FDA panel endorses lifting restrictions on four peptides for compounding pharmacies use
Jul 23, 2026
🧬 Eli Lilly's (retatrutide) hits Ph3 primary endpoints with 22.6% weight loss in obesity with cardiovascular disease, J&J's Tecvayli (teclistamab) and Talvey (talquetamab) combo cuts multiple myeloma progression risk 89% in Ph3, GSK's Jideytro (zidesamtinib) wins FDA approval for ROS1-positive metastatic non-small cell lung cancer
Jul 22, 2026
🧬 Repligen to acquire BioLife Solutions for $1.5B, securing critical cryopreservation media for cell therapy market, Novartis to invest $95M in South Korea to expand radioligand therapy supply chain ecosystem, Crystalys Therapeutics raises $130M Series B to advance gout drug dotinurad through Phase 3
Jul 21, 2026
🧬 Bristol Myers Squibb, Nvidia expand AI collaboration to build “most powerful” life sciences AI infrastructure, Gilead Sciences, Merck & Co.'s (islatravir/lenacapavir) Ph3 data support first weekly oral human immunodeficiency virus treatment, Tempus AI to acquire Personalis for $1.5B, expanding cancer MRD diagnostics portfolio
Jul 20, 2026
🧬 Samsung Biologics launches all-cash tender offer to acquire PolyPeptide for ~CHF 1.46B ($1.81B), expanding peptide CDMO capabilities, UK biotech financing hits five-year high with £2.11B ($2.84B) equity investment in Q2 2026, Scribe Therapeutics plans $96M IPO to advance lipid-lowering CRISPR genetic medicines
Jul 17, 2026
🧬 Jasper Therapeutics merges with Kira Pharmaceuticals, gaining differentiated complement portfolio including dual-inhibitor KP-104, Takeda's (zasocitinib) clears scalp psoriasis in 75% of patients in Ph3 moderate-to-severe plaque psoriasis trials, Novartis' Fabhalta (iptacopan) receives FDA traditional approval to slow kidney function decline in primary immunoglobulin A nephropathy
Jul 16, 2026
🧬 FDA approves Merck & Co.'s Lipfendra (enlicitide), first oral PCSK9 inhibitor pill, for hypercholesterolemia including heterozygous familial hypercholesterolemia, Eli Lilly to acquire AtaiBeckley for up to $3.8B, marking pharma's first psychedelics push into depression treatment, Johnson & Johnson raises 2026 guidance as Tremfya hits $2B and Icotyde launch exceeds expectations
Jul 15, 2026
🧬 FDA approves Celcuity's Revtorpyk (gedatolisib) for PI3K pathway hormone receptor-positive, HER2-negative metastatic breast cancer after Ph3 success, Insilico Medicine, Bora Pharmaceuticals partner on AI drug discovery and commercialization, deal worth $2.5B, Kelun-Biotech's (sacituzumab tirumotecan) plus Merck & Co.'s Keytruda meets primary endpoint in Ph3 for PD-L1-negative non-squamous non-small cell lung cancer
Jul 14, 2026
🧬 Biogen's (diranersen) Ph2 results show tau-targeting antisense oligonucleotide slows decline in Alzheimer's disease, AstraZeneca, Dizal Pharmaceutical strike exclusive global lung cancer license deal, $600M upfront, up to $1.5B total, Biogen, Eisai win FDA approval for subcutaneous Leqembi (lecanemab) initiation therapy in Alzheimer's disease
Jul 13, 2026
🧬 FDA expands Pfizer and Astellas' Padcev (enfortumab vedotin-ejfv) plus Merck & Co.'s Keytruda (pembrolizumab) label to all muscle-invasive bladder cancer patients regardless of cisplatin eligibility, Bayer, Apollo strike €3B ($3.43B) equity deal for minority stake in LARC contraceptives business, CMS, Insilico partner on AI-driven CNS drug discovery, $177M milestones
Jul 10, 2026
🧬 Sanofi's Sarclisa Escena (isatuximab) wins FDA approval as first on-body injector anticancer drug for multiple myeloma, GSK, Hansoh Pharmaceutical's (risvutatug rezetecan) Ph3 trial meets overall survival endpoint in small cell lung cancer, ARPA-H awards up to $160M to teams developing personalized genetic medicines for rare diseases
Jul 9, 2026
🧬 Ipsen's Dysport (abobotulinumtoxinA) meets Ph3 goals in both episodic and chronic migraine trials, Sanofi offers EU concessions to halt probe over misleading flu vaccine campaign against CSL Seqirus, MindRank raises $52M Series B, advancing AI-discovered oral GLP-1 obesity pill to Phase III
Jul 8, 2026
🧬 Vera Therapeutics' Trutakna (atacicept) receives FDA accelerated approval for IgA nephropathy targeting APRIL and BAFF, AstraZeneca, Sino Biopharmaceutical strike ex-China licensing deal for COPD candidate TQC3721, $200M upfront, up to $1.9B total, Evonik invests $100M in Indiana API plant to meet surging U.S. CDMO demand
Jul 7, 2026
🧬 Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B in largest-ever deal, expanding into endocrine diseases, Kalohexis files confidential IPO, developing melanocortin-based obesity and cancer cachexia treatments, Compass Pathways' COMP360 (psilocybin) demonstrates durable Ph3 response in treatment-resistant depression
